Another study reported that the OS in BRAF-targeted therapy was longer (56.5 months) than that of conventionally treated patients (27.2 months), further emphasizing the importance of targeting treatments for BRAF V600E mutated NSCLC (23). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.